Greystone Capital analyzes 2025 performance while maintaining high conviction in Natural Resource Partners and KITS Eyecare.

Counterpoint Quantitative Equity ETF (CPAI) review: it beat markets, has elevated risks. Read here for a detailed investment ...

Trump administration drops plans for U.S. critical minerals price floors, hitting rare earth stocks after-hours.

Hold rating as valuation leaves little upside. My DCF-derived intrinsic value is $665.56 per share. See more analysis here.

Fossil Group has had a challenging decade behind the company. Weak secular market trends and operational missteps weigh on ...

Wall Street expects a record quarter for Apple with ~$138.5B in revenue and a focus on the iPhone 17 "supercycle" and ...

NEOS Nasdaq-100® Hedged Equity Income ETF’s 9% yield using calls for income and a put-spread on the NASDAQ-100. See here for ...

AI-driven capex surges to $115B–$135B for 2026, Reality Labs drag, upside outlook. Click for this updated look at META.

Tesla, Inc. beats earnings as margins rise, but the 2026 delivery outlook stays vague amid demand worries. Click for this ...

Dynex Capital, Inc. is rated a Sell due to temporary gains and long-term underperformance versus the market persists. Read ...

Angel Oak Mortgage REIT hold reaffirmed: portfolio growth, 14% yield, Brookfield tie-up, plus non-QM and rate risks.

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns.